基于缺血性卒中病因与发病机制分型的早期干预策略.ppt

26.01.08: Subcutaneous unfractionated heparin (UFH) at low or moderate doses {International-Stroke-Trial-Collaborative-Group, 1997 #908}, nadroparin {Kay, 1995 #215;Wong, 2007 #477}; certoparin {Diener, 2001 #53}, tinzaparin {Bath, 2001 #15}, dalteparin {Berge, 2000 #21} and intravenous danaparoid {The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators, 1998 #216} have failed to show an overall benefit of anticoagulation when initiated within 24 to 48 hours from stroke onset. Improvements in outcome or reductions in stroke recurrence rates w